Correlation between fertility drugs use and malignant melanoma incidence: the state of the art

Tumor Biology

Volumn 35, Issue 9, 2014, Pages 8415-8424

  Tomao, Federica ^a   Papa, Anselmo ^a   Lo Russo, Giuseppe ^a   Zuber, Sara ^a   Spinelli, Gian Paolo ^a   Rossi, Luigi ^a   Caruso, Davide ^a   Prinzi, Natalie ^a   Stati, Valeria ^a   Benedetti Panici, Pierluigi ^a   Tomao, Silverio ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Fertility drugs; In vitro fertilization; Infertility; Invasive melanoma; Ovarian stimulation

Indexed keywords

AROMATASE INHIBITOR; BUSERELIN; CETRORELIX; CHORIONIC GONADOTROPIN; CLOMIFENE; CLOMIFENE CITRATE; FERTILITY PROMOTING AGENT; FOLLITROPIN; GONADORELIN; GONADORELIN DERIVATIVE; HUMAN MENOPAUSAL GONADOTROPIN; LEUPRORELIN; LUTEINIZING HORMONE; NAFARELIN; PROGESTERONE;

CANCER MORTALITY; CANCER PROGNOSIS; CANCER RISK; CUTANEOUS MELANOMA; DRUG USE; FEMALE FERTILITY; FEMALE INFERTILITY; HUMAN; MELANOMA; META ANALYSIS (TOPIC); PREGNANCY; REVIEW; SYSTEMATIC REVIEW (TOPIC); CHEMICALLY INDUCED; FEMALE; INCIDENCE; RISK ASSESSMENT; RISK FACTOR; SKIN NEOPLASMS;

FEMALE; FERTILITY AGENTS, FEMALE; HUMANS; INCIDENCE; MELANOMA; RISK ASSESSMENT; RISK FACTORS; SKIN NEOPLASMS;

EID: 84919863003     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-2230-4     Document Type: Review

References (68)

1. Markovic SN, Erickson LA, Rao RD, Weenig RH, Pockaj BA, Bardia A, et al. Melanoma Study Group of the Mayo Clinic Cancer Center. Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis. Mayo Clin Proc. 2007;82(3):364–80.
2. Siegel R, Ma J, Zou Z, Jemal A. Cancer Statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29.
3. Joosse A, Collette S, Suciu S, Nijsten T, Lejeune F, Kleeberg UR, et al. Superior outcome of women with stage I/II cutaneous melanoma: pooled analysis of four European Organisation for Research and Treatment of Cancer phase III trials. J Clin Oncol. 2012;30(18):2240–7.
4. Joosse A, de Vries E, Eckel R, Nijsten T, Eggermont AM, Hölzel D, et al. Gender differences in melanoma survival: female patients have a decreased risk of metastasis. J Invest Dermatol. 2011;131(3):719–26.
5. Kemeny MM, Busch E, Stewart AK, Menck HR. Superior survival of young women with malignant melanoma. Am J Surg. 1998;175(6):437–44.
6. Conybeare RC. Malignant melanoma and pregnancy: report of 3 cases. Obstet Gynecol. 1964;24:451–4.
7. Jhaveri MB, Driscoll MS, Grant-Kels JM. Melanoma in pregnancy. Clin Obstet Gynecol. 2011;54(4):537–45.
8. Kaae J, Andersen A, Boyd HA, Wohlfahrt J, Melbye M. Reproductive history and cutaneous malignant melanoma: a comparison between women and men. Am J Epidemiol. 2007;165(11):1265–70.
9. Houghton AN, Flannery J, Viola MV. Malignant melanoma of the skin occurring during pregnancy. Cancer. 1981;48(2):407–10.
10. Lens MB, Rosdahl I, Ahlbom A, Farahmand BY, Synnerstad I, Boeryd B, et al. Effect of pregnancy on survival in women with cutaneous malignant melanoma. J Clin Oncol. 2004;22(21):4369–75.
11. Silipo V, De Simone P, Mariani G, Buccini P, Ferrari A, Catricala C. Malignant melanoma and pregnancy. Melanoma Res. 2006;16(6):497–500.
12. O' Meara AT, Cress R, Xing G, Danielsen B, Smith LH. Malignant melanoma in pregnancy. A population-based evaluation. Cancer. 2005;103(6):26–1217.
13. Zhou JH, Kim KB, Myers JN, Fox PS, Ning J, Bassett RL, et al. Immunohistochemical expression of hormone receptors in melanoma of pregnant women, non pregnant women, and men. Am J Dermatopathol. 2014;36(1):74–9.
14. Schmidt AN, Nanney LB, Boyd AS, King Jr LE, Ellis DL. Oestrogen receptor-beta expression in melanocytic lesions. Exp Dermatol. 2006;15(12):971–80.
15. de Giorgi V, Mavilia C, Massi D, Gozzini A, Aragona P, Tanini A, et al. Estrogen receptor expression in cutaneous melanoma: a real-time reverse transcriptase-polymerase chain reaction and immunohistochemical study. Arch Dermatol. 2009;145(1):30–6.
16. Beral V, Ramcharan S, Faris R. Malignant melanoma and oral contraceptive use among women in California. Br J Cancer. 1977;36(6):804–9.
17. Pfahlberg A, Hassan K, Wille L, Lausen B, Gefeller O. Systematic review of case–control studies: oral contraceptives show no effect on melanoma risk. Public Health Rev. 1997;25(3–4):309–15.
18. Gefeller O, Hassan K, Wille L. Cutaneous malignant melanoma in women and the role of oral contraceptives. Br J Dermatol. 1998;138(1):122–4.
19. Karagas MR, Stukel TA, Dykes J, Miglionico J, Greene MA, Carey M, et al. A pooled analysis of 10 case–control studies of melanoma and oral contraceptive use. Br J Cancer. 2002;86(7):1085–92.
20. Leslie KK, Espey E. Oral contraceptives and skin cancer is there a link? Am J Clin Dermatol. 2005;6(6):349–55.
21. Gandini S, Iodice S, Koomen ER, Pietro AD, Sera F, Caini S. Hormonal and reproductive factors in relation to melanoma in women: current review and meta-analysis. Eur J Cancer. 2011;47(17):2607–17.
22. Pack GT, Scharnagel IM. The prognosis of malignant melanoma in pregnant woman. Cancer. 1951;4(2):324–34.
23. Byrd BF, McGanity WJ. The effect of pregnancy on the clinical course of malignant melanoma. South Med J. 1954;47(3):196–200.
24. Sutherland CM, Loutfi A, Mather FJ, Carter RD, Krementz ET. Effect of pregnancy upon malignant melanoma. Surg Gynecol Obstet. 1983;157(5):443–6.
25. Trapeznikov NN, Khasanov SR, Iavorskiĭ VV. Melanoma of the skin and pregnancy. Vopr Onkol. 1987;33(6):40–6.
26. Holly EA. Melanoma and pregnancy. Recent Results Cancer Res. 1986;102:118–26.
27. McManamny DS, Moss AL, Pocock PV, Briggs JC. Melanoma and pregnancy: a long-term follow-up. Br J Obstet Gynaecol. 1989;96(12):1419–23.
28. Wong JH, Sterns EE, Kopald KH, Nizze JA, Morton DL. Prognostic significance of pregnancy in stage I melanoma. Arch Surg. 1989;124:1227–31.
29. Osterlind A, Tucker MA, Stone BJ, Jensen OM. The Danish case–control study of cutaneous malignant melanoma. III Hormonal and reproductive factors in women Int J Cancer. 1988;42:821–4.
30. Lambe M, Thörn M, Sparén P, Bergström R, Adami HO. Malignant melanoma: reduced risk associated with early childbearing and multiparity. Melanoma Res. 1996;6:147–53.
31. Karagas MR, Zens MS, Stukel TA, Swerdlow AJ, Rosso S, Osterlind A, et al. Pregnancy history and incidence of melanoma in women: a pooled analysis. Cancer Causes and Control. 2006;17(1):11–9.
32. Goldstein SR, Siddhanti S, Ciaccia AV, Plouffe Jr L. A pharmacological review of selective oestrogen receptor modulators. Hum Reprod Update. 2000;6(3):212–24.
33. Practice Committee of the American Society for Reproductive Medicine. Use of clomiphene citrate in women. Fertil Steril. 2004;82 Suppl 1:S90-6.
34. Practice Committee of the American Society for Reproductive Medicine. Use of clomiphene citrate in infertile women: a committee opinion. Fertil Steril. 2013;100(2):341–8.
35. Diedrich K, Felberbaum R. New approaches to ovarian stimulation. Hum Reprod. 1998;13 Suppl 3:1–13.
36. Leibowitz D, Hoffman J. Fertility drug therapies: past, present, and future. J Obstet Gynecol Neonatal Nurs. 2000;29(2):201–10.
37. Holzer H, Casper R, Tulandi T. A new era in ovulation induction. Fertil Steril. 2006;85(2):277–84.
38. Hilliard TS, Modi DA, Burdette JE. Gonadotropins activate oncogenic pathways to enhance proliferation in normal mouse ovarian surface epithelium. Int J Mol Sci. 2013;14(3):4762–82.
39. Lo Russo G, Spinelli GP, Tomao S, Rossi B, Frati L, Panici PB, et al. Breast cancer risk after exposure to fertility drugs. Expert Rev Anticancer Ther. 2013;13(2):149–57.
40. Schüler S, Ponnath M, Engel J, Ortmann O. Ovarian epithelial tumors and reproductive factors: a systematic review. Arch Gynecol Obstet. 2013;287(6):1187–204.
41. Sergentanis TN, Diamantaras AA, Perlepe C, Kanavidis P, Skalkidou A, Petridou ET. IVF and breast cancer: a systematic review and meta-analysis. Hum Reprod Update. 2014;20(1):106–23.
42. Tomao F, Lo Russo G, Spinelli GP, Tomao S. Clinical use of fertility agents and risk of breast cancer: a recent update for an old problem. Curr Opin Obstet Gynecol. 2014;26(3):130–7.
43. Tomao F, Lo Russo G, Spinelli GP, Stati V, Prete AA, Prinzi N, et al. Fertility drugs, reproductive strategies and ovarian cancer risk. J Ovarian Res. 2014;8:7–51.
44. Ron E, Lunenfeld B, Menczer J, Blumstein T, Katz L, Oelsner G, et al. Cancer incidence in a cohort of infertile women. Am J Epidemiol. 1987;125(5):780–90.
45. Brinton LA, Melton 3rd LJ, Malkasian Jr GO, Bond A, Hoover R. Cancer risk after evaluation for infertility. Am J Epidemiol. 1989;129(4):712–22.
46. Rossing MA, Daling JR, Weiss NS, Moore DE, Self SG. Risk of cutaneous melanoma in a cohort of infertile women. Melanoma Res. 1995;5(2):123–7.
47. Venn A, Watson L, Lumley J, Giles G, King C, Healy D. Breast and ovarian cancer incidence after infertility and in vitro fertilisation. Lancet. 1995;346(8981):995–1000.
48. Modan B, Ron E, Lerner-Geva L, Blumstein T, Menczer J, Rabinovici J, et al. Cancer incidence in a cohort of infertile women. Am J Epidemiol. 1998;147(11):1038–42.
49. Young P. Purdie 0, Jackman L, Molloy 0. Green A A study of infertility treatment and melanoma Melanoma Res. 2001;11(5):535–41.
50. Althuis MD, Scaccia B, Lamb EJ, Moghissi KS, Westhoff CL, Mabie JE, et al. Melanoma, thyroid, cervical, and colon cancer risk after use of fertility drugs. Am J Obstet Gynecol. 2005;193(3 Pt 1):668–74.
51. Hannibal CG, Jensen A, Sharif H, Kjaer SK. Malignant melanoma risk after exposure to fertility drugs: results from a large Danish cohort study. Cancer Causes Control. 2008;19(7):759–65.
52. Silva Idos S, Wark PA, McCormack VA. Mayer 0, Overton C, Little V, et al. Ovulation-stimulation drugs and cancer risks: a long-term follow-up of a British cohort Br J Cancer. 2009;100(11):1824–31.
53. Calderon-Margalit R, Friedlander Y, Yanetz R, Kleinhaus K, Perrin MC. Manor 0, et al. Cancer risk after exposure to treatments for ovulation induction Am J Epidemiol. 2009;169(3):365–75.
54. Yli-Kuha AN, Gissler M, Klemetti R, Luoto R, Hemminki E. Cancer morbidity in a cohort of 9,175 Finnish women treated for infertility. Hum Reprod. 2012;27(4):1149–55.
55. Stewart LM, Holman CD, Finn JC, Preen DB, Hart R. Association between in-vitro fertilization, birth and melanoma. Melanoma Res. 2013;23(6):489–95.
56. Snell RS, Bischitz PG. The effect of large doses of estrogen and estrogen and progesterone on melanin pigmentation. J Invest Dermatol. 1960;35:73–82.
57. Thornton M, Taylor AH, Mulligan K, AI-Azzawi F, Lyon CC, O'Driscoll J, et al. The distribution of estrogen receptor beta is distinct to that of estrogen receptor alpha and the androgen receptor in human skin and the pilosebaceous unit. J Investig Dermatol Symp. 2003;8(1):3–100.
58. Ohata C, Tadokoro T, Itami S. Expression of estrogen receptor beta in normal skin, melanocytic nevi and malignant melanomas. J Dermatol. 2008;35(4):215–21.
59. Kvaskoff M, Bijon A, Mesrine S, Boutron-Ruault MC, Clavel-Chapelon F. Cutaneous melanoma and endogenous hormonal factors: a large French prospective study. Am J Epidemiol. 2011;173(10):1192–202.
60. eskanich 0, Hunter OJ, Willett WC, Spiegelman 0, Stampfer MJ, Speizer FE, et al. Oral contraceptive use and risk of melanoma in premenopausal women. Br J Cancer. 1999;81 (5):918–23.
61. Koomen ER, Joosse A, Herings RM, Casparie MK, Guchelaar HJ, Nijsten T. Estrogens, oral contraceptives and hormonal replacement therapy increase the incidence of cutaneous melanoma: a population-based case–control study. Ann Oncol. 2009;20(2):358–64.
62. Garbe C, Leiter U. Melanoma epidemiology and trends. Clin Dermatol. 2009;27(1):3–9.
63. Gandini S, Sera F, Callaruzza MS, Pasquini P. Picconi 0, Boyle P, et al. Meta-analysis of risk factors for cutaneous melanoma: II Sun exposure Eur J Cancer. 2005;41(1):45–60.
64. Veierød MB, Weiderpass E, Thom M, Hansson J, Lund E, Armstrong B, et al. A prospective study of pigmentation, sun exposure, and risk of cutaneous malignant melanoma in women. J Natl Cancer Inst. 2003;95(20):1530–8.
65. Nielsen K, Masback A, Olsson H, Ingvar C. A prospective, population-based study of 40000 women regarding host factors, UV exposure and sunbed use in relation to risk and anatomic site of cutaneous melanoma. Int J Cancer. 2012;131(3):706–15.
66. Levine H, Afek A, Shamiss A, Derazne E. Tzur 0, Astman N, et al. Country of origin, age at migration and risk of cutaneous melanoma: a migrant cohort study of 1,100,000 Israeli men. Int J Cancer. 2013;133(2):486–94.
67. Polyzos NP, Tzioras S, Badawy AM, Valachis A, Dritsas C, Mauri D. Aromatase inhibitors for female infertility: a systematic review of the literature. Reprod Biomed Online. 2009;19(4):456–71.
68. Polyzos NP, Tzioras S, Mauri D, Tsappi M, Cortinovis I, Tsali L, et al. Treatment of unexplained infertility with aromatase inhibitors or clomiphene citrate: a systematic review and meta-analysis. Obstet Gynecol Surv. 2008;63(7):472–9.